ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Topotecan

Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.

Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.

Drug pageTopotecan: every studyMany companies study it; this page follows only the 33 they lead. All 251 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 14, 200233 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline180 open or runningphase 3since Aug 14, 2002Nov 2, 1999none ahead
Bristol-Myers Squibbits history only20 open or runningphase 2since Sep 10, 2005Sep 10, 2005none ahead
AbbVieits history only10 open or runningphase 3since Dec 10, 2015Dec 10, 2015none ahead
Advenchen Laboratoriesits history only11 open or runningphase 3since Aug 28, 2015Aug 28, 2015none ahead
Ascenta Therapeuticsits history only10 open or runningphase 2since Nov 7, 2006Nov 7, 2006none ahead
AstraZenecaits history only10 open or runningphase 2since Apr 10, 2001Apr 10, 2001none ahead
BioNTechits history only11 open or runningphase 2since Jun 3, 2024Jun 3, 2024Jun 2027phase 2 · NCT06449209
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 2since Mar 6, 2012Mar 6, 2012none ahead
Gilead Sciencesits history only11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834
Hoffmann-La Rocheits history only10 open or runningphase 3since Sep 11, 2012Sep 11, 2012none ahead

Also a collaborator on its studies: Eisai, Baili-Bio (Chengdu) Pharmaceutical and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 2, 1999.

  1. Nov 18, 2002Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00049998 · 760 enrolled · Australia, Austria, Belgium and more
  2. May 23, 2003Phase 2 study in Ovarian NeoplasmsNCT00061308 · 75 enrolled · United States, Canada
  3. Jul 17, 2003Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00065182 · 399 enrolled · United States, Canada, Poland
  4. Sep 8, 2005Phase 1 study in Carcinoma, Renal CellNCT00158886 · 26 enrolled · United States
  5. Nov 30, 2005Phase 1 study in Small Cell Lung CarcinomaNCT00259935 · 107 enrolled · United States, Netherlands
  6. Dec 20, 2005Phase 2 study in Endometrial NeoplasmsNCT00267488 · 70 enrolled · United States, Canada, Hungary
  7. Jan 11, 2006Phase 3 study in Small Cell Lung CarcinomaNCT00276276 · 141 enrolled · Bulgaria, Hungary, Netherlands and more
  8. May 1, 2006Phase 3 study in Small Cell Lung CarcinomaNCT00320359 · 700 enrolled · Austria, Germany
  9. Aug 7, 2006Phase 1 study in NeoplasmsNCT00361803 · 15 enrolled · United States
  10. Oct 19, 2006Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00390806 · 472 enrolled · United States, Canada, Hungary and more
  11. Feb 15, 2007Phase 2 study in Breast NeoplasmsNCT00437073 · 22 enrolled · United States, Austria, Belgium and more
  12. Jun 5, 2007Phase 1 study in NeoplasmsNCT00483860 · 59 enrolled · United States, Korea, Republic of, Netherlands
  13. Jun 16, 2008Phase 2 study in Small Cell Lung CarcinomaNCT00698516 · 50 enrolled · United States
  14. Aug 11, 2008Phase 1 study in Solid TumoursNCT00732420 · 68 enrolled · United States, Netherlands

TargetBeta

TOP1 →read by rule
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule

Other programs on TOP1

ProgramCompanyFurthest phaseStudies
irinotecan sucrosofateruleCSPC Pharmaceutical Groupphase 320

Studies

All 18 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00732420Solid Tumours · United States, Netherlands1CompletedJun 12, 201368
NCT00698516Small Cell Lung Carcinoma · United States2CompletedMay 201050
NCT00483860Neoplasms · United States, Korea, Republic of, Netherlands1CompletedFeb 6, 201259
NCT00437073Breast Neoplasms · United States, Austria, Belgium and more2TerminatedJan 200922
NCT00390806Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more3CompletedJul 2012472
NCT00361803Neoplasms · United States1CompletedAug 9, 200715
NCT00320359Small Cell Lung Carcinoma · Austria, Germany3CompletedFeb 2007700
NCT00276276Small Cell Lung Carcinoma · Bulgaria, Hungary, Netherlands and more3Completed141
NCT00267488Endometrial Neoplasms · United States, Canada, Hungary2CompletedDec 200770
NCT00259935Small Cell Lung Carcinoma · United States, Netherlands1CompletedJul 5, 2007107
NCT00158886Carcinoma, Renal Cell · United States1TerminatedAug 11, 200626
NCT00065182Carcinoma, Non-Small-Cell Lung · United States, Canada, Poland2CompletedAug 30, 2007399
NCT00061308Ovarian Neoplasms · United States, Canada2CompletedSep 200475
NCT00049998Carcinoma, Non-Small-Cell Lung · Australia, Austria, Belgium and more3CompletedApr 2004760
NCT00046111Small Cell Lung Carcinoma · United States, Canada1CompletedApr 20041
NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more3CompletedJan 2004760
NCT00043862Small Cell Lung Carcinoma · United States2CompletedNov 200560
NCT00002395HIV Infections · United States2Completed54

How it is read

Names in the registry

  • “Topotecan”, 15 entries
  • “topotecan”, 11 entries
  • “topotecan hydrochloride”, 2 entries
  • “Topotecan/Docetaxel combination”, 1 entry
  • “Topotecan (Chemotherapy)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.